TipRanks
Advertisement
Advertisement
Kazia Therapeutics Gains $2 Million Milestone as Sovargen Doses First Paxalisib Patient in Rare Epilepsy Trial
PremiumCompany AnnouncementsKazia Therapeutics Gains $2 Million Milestone as Sovargen Doses First Paxalisib Patient in Rare Epilepsy Trial
1M ago
Kazia Therapeutics licensee doses first patient in Phase 1b/2a paxalisib trial
Premium
The Fly
Kazia Therapeutics licensee doses first patient in Phase 1b/2a paxalisib trial
1M ago
Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq
Premium
Company Announcements
Kazia Therapeutics Switches ADR Depositary to JPMorgan as ADSs Remain on Nasdaq
1M ago
Kazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer
PremiumThe FlyKazia Therapeutics expands paxalisib trial into HR+/HER2- breast cancer
2M ago
Kazia Therapeutics Unveils New Investor-Focused Website
Premium
Company Announcements
Kazia Therapeutics Unveils New Investor-Focused Website
2M ago
Kazia Therapeutics Secures $40 Million U.S. Offering to Accelerate Paxalisib Oncology Program
Premium
Company Announcements
Kazia Therapeutics Secures $40 Million U.S. Offering to Accelerate Paxalisib Oncology Program
2M ago
Kazia Therapeutics reports 100% clinical benefit rate in breast cancer treatment
PremiumThe FlyKazia Therapeutics reports 100% clinical benefit rate in breast cancer treatment
2M ago
Kazia Therapeutics announces offering of ADS, warrants
Premium
The Fly
Kazia Therapeutics announces offering of ADS, warrants
2M ago
Kazia Therapeutics initiated with a Buy at Canaccord
Premium
The Fly
Kazia Therapeutics initiated with a Buy at Canaccord
2M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―